Example of Molecular Pharmaceutics format
Recent searches

Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format Example of Molecular Pharmaceutics format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Molecular Pharmaceutics — Template for authors

Categories Rank Trend in last 3 yrs
Pharmaceutical Science #19 of 166 down down by 10 ranks
Drug Discovery #23 of 145 down down by 12 ranks
Molecular Medicine #33 of 167 down down by 7 ranks
journal-quality-icon Journal quality:
High
calendar-icon Last 4 years overview: 1804 Published Papers | 14537 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 18/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access
recommended Recommended

American Chemical Society

Quality:  
High
CiteRatio: 6.5
SJR: 0.976
SNIP: 1.593
open access Open Access
recommended Recommended

Elsevier

Quality:  
High
CiteRatio: 7.3
SJR: 1.045
SNIP: 1.333
open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 8.2
SJR: 1.864
SNIP: 1.641
open access Open Access
recommended Recommended

American Chemical Society

Quality:  
High
CiteRatio: 10.6
SJR: 2.01
SNIP: 1.791

Journal Performance & Insights

Impact Factor

CiteRatio

Determines the importance of a journal by taking a measure of frequency with which the average article in a journal has been cited in a particular year.

A measure of average citations received per peer-reviewed paper published in the journal.

4.321

2% from 2018

Impact factor for Molecular Pharmaceutics from 2016 - 2019
Year Value
2019 4.321
2018 4.396
2017 4.556
2016 4.44
graph view Graph view
table view Table view

8.1

8% from 2019

CiteRatio for Molecular Pharmaceutics from 2016 - 2020
Year Value
2020 8.1
2019 7.5
2018 7.4
2017 8.2
2016 8.4
graph view Graph view
table view Table view

insights Insights

  • Impact factor of this journal has decreased by 2% in last year.
  • This journal’s impact factor is in the top 10 percentile category.

insights Insights

  • CiteRatio of this journal has increased by 8% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.13

7% from 2019

SJR for Molecular Pharmaceutics from 2016 - 2020
Year Value
2020 1.13
2019 1.213
2018 1.402
2017 1.572
2016 1.538
graph view Graph view
table view Table view

1.113

2% from 2019

SNIP for Molecular Pharmaceutics from 2016 - 2020
Year Value
2020 1.113
2019 1.132
2018 1.182
2017 1.254
2016 1.213
graph view Graph view
table view Table view

insights Insights

  • SJR of this journal has decreased by 7% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has decreased by 2% in last years.
  • This journal’s SNIP is in the top 10 percentile category.
Molecular Pharmaceutics

Guideline source: View

Potential, possible, or probable predatory scholarly open-access publishers.

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

American Chemical Society

Molecular Pharmaceutics

Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery ...... Read More

Pharmaceutical Science

Drug Discovery

Molecular Medicine

Pharmacology, Toxicology and Pharmaceutics

i
Last updated on
18 Jun 2020
i
ISSN
1543-8384
i
Impact Factor
High - 1.314
i
Open Access
Yes
i
Sherpa RoMEO Archiving Policy
White faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
ACS Custom Citation (achemso)
i
Citation Type
Numbered (Superscripted)
25
i
Bibliography Example
Beenakker, C. W. J. Specular Andreev Reflection in Graphene. Phys. Rev. Lett. 2006, 97, 067007.

Top papers written in this journal

Journal Article DOI: 10.1021/MP700113R
Bioavailability of curcumin: problems and promises.
Preetha Anand1, Ajaikumar B. Kunnumakkara1, Robert A. Newman1, Bharat B. Aggarwal
14 Nov 2007 - Molecular Pharmaceutics

Abstract:

Curcumin, a polyphenolic compound derived from dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Phase I clinical trials have shown that curcumin is safe even at high doses (12 g/day) in humans but exhibit poor bioavailabi... Curcumin, a polyphenolic compound derived from dietary spice turmeric, possesses diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Phase I clinical trials have shown that curcumin is safe even at high doses (12 g/day) in humans but exhibit poor bioavailability. Major reasons contributing to the low plasma and tissue levels of curcumin appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination. To improve the bioavailability of curcumin, numerous approaches have been undertaken. These approaches involve, first, the use of adjuvant like piperine that interferes with glucuronidation; second, the use of liposomal curcumin; third, curcumin nanoparticles; fourth, the use of curcumin phospholipid complex; and fifth, the use of structural analogues of curcumin (e.g., EF-24). The latter has been reported to have a rapid absorption with a peak plasma half-life. Despite the lower bioavailability, therapeutic efficacy of... read more read less

Topics:

Liposomal Curcumin (75%)75% related to the paper, Curcumin (59%)59% related to the paper, Curcuminoid (57%)57% related to the paper, Bioavailability (53%)53% related to the paper, Piperine (51%)51% related to the paper
4,275 Citations
open accessOpen access Journal Article DOI: 10.1021/MP800051M
Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles
Frank Alexis1, Eric M. Pridgen2, Linda K. Molnar2, Omid C. Farokhzad2
04 Aug 2008 - Molecular Pharmaceutics

Abstract:

Nanoparticle (NP) drug delivery systems (5−250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biological barriers and releasing a therapeutic load in the optimal dosage range. Rapid clearance of circulating nanoparticles during systemic delivery is a critical issue fo... Nanoparticle (NP) drug delivery systems (5−250 nm) have the potential to improve current disease therapies because of their ability to overcome multiple biological barriers and releasing a therapeutic load in the optimal dosage range. Rapid clearance of circulating nanoparticles during systemic delivery is a critical issue for these systems and has made it necessary to understand the factors affecting particle biodistribution and blood circulation half-life. In this review, we discuss the factors which can influence nanoparticle blood residence time and organ specific accumulation. These factors include interactions with biological barriers and tunable nanoparticle parameters, such as composition, size, core properties, surface modifications (pegylation and surface charge), and finally, targeting ligand functionalization. All these factors have been shown to substantially affect the biodistribution and blood circulation half-life of circulating nanoparticles by reducing the level of nonspecific uptake, de... read more read less

Topics:

Drug delivery (52%)52% related to the paper, Biodistribution (51%)51% related to the paper, PEGylation (51%)51% related to the paper
View PDF
3,009 Citations
Journal Article DOI: 10.1021/MP800049W
Pharmacokinetics and biodistribution of nanoparticles.
Shyh-Dar Li1, Leaf Huang1
09 Jul 2008 - Molecular Pharmaceutics

Abstract:

Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity. Chemical and physical... Nanoparticles show their promise for improving the efficacy of drugs with a narrow therapeutic window or low bioavailability, such as anticancer drugs and nucleic acid-based drugs. The pharmacokinetics (PK) and tissue distribution of the nanoparticles largely define their therapeutic effect and toxicity. Chemical and physical properties of the nanoparticles, including size, surface charge, and surface chemistry, are important factors that determine their PK and biodistribution. The intracellular fate of the nanoparticles after cellular internalization that affects the drug bioavailability is also discussed. Strategies for overcoming barriers for intracellular delivery and drug release are presented. Finally, future directions for improving the PK of nanoparticles and perspectives in the field are discussed. read more read less

Topics:

Nanomedicine (54%)54% related to the paper
1,380 Citations
Journal Article DOI: 10.1021/MP900015Y
The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic
Mark E. Davis1
03 Apr 2009 - Molecular Pharmaceutics

Abstract:

Experimental therapeutics developed to exploit RNA interference (RNAi) are now in clinical studies. Here, the translation from concept to clinic for the first experimental therapeutic to provide targeted delivery of synthetic, small interfering RNA (siRNA) in humans is described. This targeted, nanoparticle formulation of siR... Experimental therapeutics developed to exploit RNA interference (RNAi) are now in clinical studies. Here, the translation from concept to clinic for the first experimental therapeutic to provide targeted delivery of synthetic, small interfering RNA (siRNA) in humans is described. This targeted, nanoparticle formulation of siRNA, denoted as CALAA-01, consists of a cyclodextrin-containing polymer (CDP), a polythethylene glycol (PEG) steric stabilization agent, and human transferrin (Tf) as a targeting ligand for binding to transferrin receptors (TfR) that are typically upregulated on cancer cells. The four component formulation is self-assembled into nanoparticles in the pharmacy and administered intravenously (iv) to patients. The designed features of this experimental therapeutic are described, and their functions illustrated. read more read less

Topics:

Small interfering RNA (53%)53% related to the paper, Transferrin receptor (50%)50% related to the paper
View PDF
958 Citations
open accessOpen access Journal Article DOI: 10.1021/MP800032F
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.
Marina A. Dobrovolskaia1, Parag Aggarwal1, Jennifer B. Hall1, Scott E. McNeil1
30 May 2008 - Molecular Pharmaceutics

Abstract:

Nanoparticles have unique physicochemical properties which make them promising platforms for drug delivery. However, immune cells in the bloodstream (such as monocytes, platelets, leukocytes, and dendritic cells) and in tissues (such as resident phagocytes) have a propensity to engulf and eliminate certain nanoparticles. A na... Nanoparticles have unique physicochemical properties which make them promising platforms for drug delivery. However, immune cells in the bloodstream (such as monocytes, platelets, leukocytes, and dendritic cells) and in tissues (such as resident phagocytes) have a propensity to engulf and eliminate certain nanoparticles. A nanoparticle’s interaction with plasma proteins (opsonins) and blood components (via hemolysis, thrombogenicity and complement activation) may influence uptake and clearance and hence potentially affect distribution and delivery to the intended target sites. Nanoparticle uptake by the immune cells is influenced by many factors. Different nanoparticles have been shown to act on different pathways, while various characteristics/properties also affect which pathway is employed for particle internalization. Nanoparticle protein binding occurs almost instantaneously once the particle enters biological medium, and the physical properties of such a particle−protein complex are often different ... read more read less
905 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Molecular Pharmaceutics.

It automatically formats your research paper to American Chemical Society formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Molecular Pharmaceutics format uses ACS Custom Citation (achemso) citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Molecular Pharmaceutics in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Molecular Pharmaceutics guidelines and auto format it.

2. Do you follow the Molecular Pharmaceutics guidelines?

Yes, the template is compliant with the Molecular Pharmaceutics guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Molecular Pharmaceutics?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Molecular Pharmaceutics citation style.

4. Can I use the Molecular Pharmaceutics templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Molecular Pharmaceutics.

5. Can I use a manuscript in Molecular Pharmaceutics that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Molecular Pharmaceutics that you can download at the end.

6. How long does it usually take you to format my papers in Molecular Pharmaceutics?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Molecular Pharmaceutics.

7. Where can I find the template for the Molecular Pharmaceutics?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Molecular Pharmaceutics's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Molecular Pharmaceutics's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Molecular Pharmaceutics an online tool or is there a desktop version?

SciSpace's Molecular Pharmaceutics is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Molecular Pharmaceutics?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Molecular Pharmaceutics?”

11. What is the output that I would get after using Molecular Pharmaceutics?

After writing your paper autoformatting in Molecular Pharmaceutics, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Molecular Pharmaceutics's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Molecular Pharmaceutics?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Molecular Pharmaceutics. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Molecular Pharmaceutics?

The 5 most common citation types in order of usage for Molecular Pharmaceutics are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Molecular Pharmaceutics?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Molecular Pharmaceutics's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Molecular Pharmaceutics in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Molecular Pharmaceutics Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Molecular Pharmaceutics formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template